Evidence mapPaperPMID 41268379Full record

ArticleFrontiers in psychiatry2025

Trends in cannabis use disorder and treatment by race and ethnicity, 2002-2019.

Mireia Triguero Roura, Aabha Vora, Evan L Eschliman, Pia M Mauro

Abstract read
In one paragraph

Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mireia Triguero RouraDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, United States.
Aabha VoraDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, United States.
Evan L EschlimanDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, United States.
Pia M MauroDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, United States.

Funding

Substance Abuse Epidemiology Training Program (SAETP) at Columbia UniversityT32DA031099 · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2025 to 2025
$582k
NIDA NIH HHS L60 DA061506NIDA NIH HHS T32 DA031099
6 · The paper itself

Abstract

Aims/background: As cannabis use continues to increase in the United States, racialized stereotypes and structural barriers to care might lead to inequitable treatment uptake across racialized groups. A greater understanding of racial disparities in cannabis treatment uptake and perceived treatment need among people with cannabis use disorder (CUD) in community-based samples is needed. Methods: Nationally representative data from the 2002-2019 National Survey on Drug Use and Health (N=1,005,421) included community-based people ages 12+ First, we assessed trends in CUD (i.e., meeting 2+ DSM-5 proxy CUD criteria) by racialized group. Among people with CUD (n=48,768), weighted logistic models regressed any CUD treatment, specialty CUD treatment, and perceived need for CUD treatment on racialized group and year, adjusting for age, gender, education, insurance, and criminal legal system exposure. We use interaction terms to examine group-specific trend differences. Results: Overall, 2.64% of the US population ages 12+ had CUD, including 2.47% of white, 1.23% of AAPI (Asian American and Pacific Islander), 4.83% of AIAN (American Indian and Alaska Native), 3.70% of Black, and 2.71% of Hispanic people. CUD increased slightly across all groups (overall annual OR: 1.01, 95% CI =1.01,1.02), with AAPI, Hispanic and people with more than one race seeing steeper increases (ORs: 1.02-1.04). Treatment use and perceived need decreased consistently and there were no group differences in these trends across racialized groups with CUD (ORs: 0.93-0.97). Black people with CUD had 21% lower odds of any treatment than white people (aOR: 0.79, 95% CI=0.65, 0.95). All racialized groups (except AAPI people) had higher odds of perceived need than white people (aORs: 1.59-1.73). Conclusion: Although all racialized groups had increasing CUD and decreasing CUD treatment use during the study period, the observed racialized disparities also persisted. For example, despite a higher prevalence of CUD among Black people compared to white people, Black people with CUD were less likely than their white counterparts to receive treatment and more likely to report perceived need. These disparities in CUD, treatment use, and perceived need underscore the need for CUD-related services overall and tailored services for racialized minorities, and especially Black people.

Indexed as

cannabis treatmentcannabis treatment needcannabis trendscannabis use disorderracialized differences

Identifiers

PMID41268379
PMCPMC12626980

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.